Can Essential Oils Provide an Alternative Adjuvant Therapy for COVID-19 Infections and Pain Management at the Same Time?

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 15; no. 11; p. 1387
• Main Authors: Damiescu, Roxana, Lee, David Y. W, Efferth, Thomas
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-11-2022; MDPI
• Subjects: addiction; Antimicrobial agents; antiviral activity; Anxiety; Aromatherapy; Care and treatment; Coronaviruses; COVID-19; Drug withdrawal; Enzymes; Epidemics; Essences and essential oils; Health aspects; Herbal medicine; Infections; inflammation; Narcotics; Nonsteroidal anti-inflammatory drugs; Oils & fats; opioid crisis; Pain; Pain management; Patients; Proteins; Review; RNA polymerase; Severe acute respiratory syndrome coronavirus 2; Viral infections; Vomiting; Germany
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15111387

The active compounds from essential oils have been an important asset in treating different diseases for many centuries. Nowadays, there are various available formulations used as food supplements to stimulate the immune system. In light of the current pandemic and the large amount of fake news circulating the internet, it is important to analyze which of the active compounds from essential oils can be successfully used in the treatment of COVID-19 infections. We analyzed the current literature on the effects of essential oils against the new SARS-CoV-2 virus to gain a better understanding of the underlying mechanisms of these compounds and establish their possible antiviral efficacy. The available studies have highlighted the antiviral potential of active compounds from essential oils, indicating that they could be used as adjuvants in treating various viral infections, including COVID-19, leading to a milder course of the disease, and improving patients’ outcomes. At the same time, these compounds relieve pain and lift the mood in comorbid patients suffering from opioid addiction. Essential oils might be useful as adjuvant tools, not only against SARS-CoV-2 but also for a subset of especially vulnerable patients affected with both COVID-19 and opioid addiction. However, randomized clinical trials are needed to determine their efficacy and develop standardized high-quality preparations that can be safely administered to the general population.